4.8 Article

Nanoparticles for cancer imaging: The good, the bad, and the promise

Journal

NANO TODAY
Volume 8, Issue 5, Pages 454-460

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.nantod.2013.06.001

Keywords

Nanonnedicine; Cancer; Imaging; Detection; Screening

Funding

  1. CCR NIH HHS [HHSN261200800001C] Funding Source: Medline
  2. NCI NIH HHS [R01 CA178748, R00 CA154006, HHSN261200800001E] Funding Source: Medline

Ask authors/readers for more resources

Recent advances in molecular imaging and nanotechnology are providing new opportunities for biomedical imaging with great promise for the development of novel imaging agents. The unique optical, magnetic, and chemical properties of materials at the scale of nanometers allow the creation of imaging probes with better contrast enhancement, increased sensitivity, controlled biodistribution, better spatial and temporal information, multi-functionality and multi-modal imaging across MRI, PET, SPECT, and ultrasound. These features could ultimately translate to clinical advantages such as earlier detection, real time assessment of disease progression and personalized medicine. However, several years of investigation into the application of these materials to cancer research has revealed challenges that have delayed the successful application of these agents to the field of biomedical imaging. Understanding these challenges is critical to take full advantage of the benefits offered by nano-sized imaging agents. Therefore, this article presents the lessons learned and challenges encountered by a group of leading researchers in this field, and suggests ways forward to develop nanoparticle probes for cancer imaging. Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available